MRFR分析によると、PD-1非小細胞肺がん治療の市場規模は2022年に24.12(10億米ドル)と推定されました。この市場は、2023年の25.67 (10億ドル) から2032年までに45.0 (10億ドル) に成長し、予測期間 (2024-2032) のCAGRは約6.44% になると予想されます。
目次
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY DRUG TYPE (USD BILLION)
6.1. Monoclonal Antibodies
6.2. Combination Therapy
6.3. Check Point Inhibitors
7. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY ADMINISTRATION ROUTE (USD BILLION)
7.1. Intravenous
7.2. Oral
7.3. Subcutaneous
8. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY TREATMENT PHASE (USD BILLION)
8.1. Adjuvant Therapy
8.2. Neoadjuvant Therapy
8.3. Palliative Care
9. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY END USER (USD BILLION)
9.1. Hospitals
9.2. Specialty Clinics
9.3. Ambulatory Surgical Centers
10. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the PD-1 Non-Small Cell Lung Cancer Treatment Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the PD-1 Non-Small Cell Lung Cancer Treatment Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. Roche
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. Janssen Pharmaceuticals
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. BristolMyers Squibb
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. Eli Lilly
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. Pfizer
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. Regeneron Pharmaceuticals
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12.6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. AstraZeneca
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. Amgen
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. Genentech
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. Seattle Genetics
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. Valeant Pharmaceuticals
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Merck and Co
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. Incyte Corporation
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. Novartis
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies
12.15. Pembrolizumab
12.15.1. Financial Overview
12.15.2. Products Offered
12.15.3. Key Developments
12.15.4. SWOT Analysis
12.15.5. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 3. NORTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 4. NORTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 5. NORTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 6. NORTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 7. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 8. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 9. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 10. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 11. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 12. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 13. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 14. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 15. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 16. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 17. EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 18. EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 19. EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 20. EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 21. EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 22. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 23. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 24. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 25. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 26. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 27. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 28. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 29. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 30. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 31. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 32. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 33. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 34. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 35. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 36. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 37. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 38. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 39. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 40. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 41. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 42. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 43. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 44. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 45. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 46. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 47. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 48. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 49. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 50. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 51. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 52. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 53. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 54. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 55. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 56. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 57. APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 58. APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 59. APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 60. APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 61. APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 62. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 63. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 64. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 65. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 66. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 67. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 68. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 69. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 70. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 71. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 72. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 73. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 74. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 75. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 76. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 77. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 78. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 79. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 80. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 81. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 82. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 83. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 84. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 85. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 86. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 87. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 88. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 89. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 90. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 91. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 92. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 93. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 94. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 95. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 96. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 97. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 98. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 99. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 100. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 101. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 102. SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 103. SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 104. SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 105. SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 106. SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 107. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 108. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 109. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 110. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 111. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 112. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 113. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 114. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 115. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 116. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 117. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 118. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 119. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 120. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 121. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 122. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 123. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 124. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 125. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 126. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 127. MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 128. MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 129. MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 130. MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 131. MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 132. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 133. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 134. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 135. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 136. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 137. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 138. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 139. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 140. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 141. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 142. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)
TABLE 143. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY ADMINISTRATION ROUTE, 2019-2032 (USD BILLIONS)
TABLE 144. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT PHASE, 2019-2032 (USD BILLIONS)
TABLE 145. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 146. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 148. ACQUISITION/PARTNERSHIP
LIST OF FIGURES
FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS
FIGURE 3. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 4. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 5. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 6. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 7. US PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 8. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 9. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 10. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 11. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 12. CANADA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 13. EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS
FIGURE 14. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 15. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 16. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 17. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 18. GERMANY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 19. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 20. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 21. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 22. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 23. UK PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 24. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 25. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 26. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 27. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 28. FRANCE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 29. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 30. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 31. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 32. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 33. RUSSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 34. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 35. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 36. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 37. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 38. ITALY PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 39. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 40. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 41. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 42. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 43. SPAIN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 44. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 45. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 46. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 47. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 48. REST OF EUROPE PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 49. APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS
FIGURE 50. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 51. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 52. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 53. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 54. CHINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 55. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 56. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 57. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 58. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 59. INDIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 60. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 61. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 62. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 63. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 64. JAPAN PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 65. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 66. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 67. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 68. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 69. SOUTH KOREA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 70. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 71. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 72. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 73. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 74. MALAYSIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 75. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 76. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 77. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 78. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 79. THAILAND PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 80. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 81. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 82. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 83. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 84. INDONESIA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 85. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 86. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 87. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 88. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 89. REST OF APAC PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 90. SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS
FIGURE 91. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 92. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 93. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 94. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 95. BRAZIL PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 96. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 97. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 98. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 99. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 100. MEXICO PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 101. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 102. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 103. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 104. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 105. ARGENTINA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 106. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 107. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 108. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 109. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 110. REST OF SOUTH AMERICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 111. MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS
FIGURE 112. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 113. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 114. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 115. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 116. GCC COUNTRIES PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 117. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 118. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 119. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 120. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 121. SOUTH AFRICA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 122. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY DRUG TYPE
FIGURE 123. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY ADMINISTRATION ROUTE
FIGURE 124. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY TREATMENT PHASE
FIGURE 125. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY END USER
FIGURE 126. REST OF MEA PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET ANALYSIS BY REGIONAL
FIGURE 127. KEY BUYING CRITERIA OF PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET
FIGURE 128. RESEARCH PROCESS OF MRFR
FIGURE 129. DRO ANALYSIS OF PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET
FIGURE 130. DRIVERS IMPACT ANALYSIS: PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET
FIGURE 132. SUPPLY / VALUE CHAIN: PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET
FIGURE 133. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY DRUG TYPE, 2024 (% SHARE)
FIGURE 134. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY DRUG TYPE, 2019 TO 2032 (USD Billions)
FIGURE 135. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
FIGURE 136. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2019 TO 2032 (USD Billions)
FIGURE 137. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY TREATMENT PHASE, 2024 (% SHARE)
FIGURE 138. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY TREATMENT PHASE, 2019 TO 2032 (USD Billions)
FIGURE 139. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY END USER, 2024 (% SHARE)
FIGURE 140. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY END USER, 2019 TO 2032 (USD Billions)
FIGURE 141. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY REGIONAL, 2024 (% SHARE)
FIGURE 142. PD-1 NON-SMALL CELL LUNG CANCER TREATMENT MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions)
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS
